Literature DB >> 25964859

Tumor-expressed IL-17D recruits NK cells to reject tumors.

Robert Saddawi-Konefka1, Timothy O'Sullivan2, Emilie T Gross1, Allen Washington1, Jack D Bui1.   

Abstract

Antitumor immunity suppresses tumorigenesis, but we do not understand how transformed cells initiate those immune responses that are essential for effective tumor immunosurveillance. Using the 3-MCA fibrosarcoma model, we identified IL-17D as a tumor-expressed cytokine that recruits natural killer cells, leading to the polarization of M1 macrophages and tumor rejection.

Entities:  

Keywords:  antitumor immunity; innate immunity; interleukin 17D; natural killer cells; tumor rejection

Year:  2015        PMID： 25964859      PMCID： PMC4353093          DOI： 10.4161/21624011.2014.954853

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  9 in total

Review 1.  T(H)17 cells in tumour immunity and immunotherapy.

Authors:  Weiping Zou; Nicholas P Restifo
Journal:  Nat Rev Immunol       Date:  2010-04       Impact factor: 53.106

2.  IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.

Authors:  V Shankaran; H Ikeda; A T Bruce; J M White; P E Swanson; L J Old; R D Schreiber
Journal:  Nature       Date:  2001-04-26       Impact factor: 49.962

3.  Interleukin-17D mediates tumor rejection through recruitment of natural killer cells.

Authors:  Timothy O'Sullivan; Robert Saddawi-Konefka; Emilie Gross; Miller Tran; Stephen P Mayfield; Hiroaki Ikeda; Jack D Bui
Journal:  Cell Rep       Date:  2014-05-01       Impact factor: 9.423

4.  Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity.

Authors:  A Diefenbach; E R Jensen; A M Jamieson; D H Raulet
Journal:  Nature       Date:  2001-09-13       Impact factor: 49.962

Review 5.  Distinct role of macrophages in different tumor microenvironments.

Authors:  Claire E Lewis; Jeffrey W Pollard
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

Review 6.  Tumour necrosis factor and cancer.

Authors:  Frances Balkwill
Journal:  Nat Rev Cancer       Date:  2009-04-03       Impact factor: 60.716

7.  Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN.

Authors:  Zvi G Fridlender; Jing Sun; Samuel Kim; Veena Kapoor; Guanjun Cheng; Leona Ling; G Scott Worthen; Steven M Albelda
Journal:  Cancer Cell       Date:  2009-09-08       Impact factor: 31.743

Review 8.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

9.  Cancer immunoediting by the innate immune system in the absence of adaptive immunity.

Authors:  Timothy O'Sullivan; Robert Saddawi-Konefka; William Vermi; Catherine M Koebel; Cora Arthur; J Michael White; Ravi Uppaluri; Daniel M Andrews; Shin Foong Ngiow; Michele W L Teng; Mark J Smyth; Robert D Schreiber; Jack D Bui
Journal:  J Exp Med       Date:  2012-08-27       Impact factor: 14.307
  9 in total
  13 in total

Review 1.  NRF2 and the Hallmarks of Cancer.

Authors:  Montserrat Rojo de la Vega; Eli Chapman; Donna D Zhang
Journal:  Cancer Cell       Date:  2018-05-03       Impact factor: 31.743

Review 2.  Interleukin 17 Family Cytokines: Signaling Mechanisms, Biological Activities, and Therapeutic Implications.

Authors:  Leticia Monin; Sarah L Gaffen
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

Review 3.  The roles and functional mechanisms of interleukin-17 family cytokines in mucosal immunity.

Authors:  Xinyang Song; Xiao He; Xiaoxia Li; Youcun Qian
Journal:  Cell Mol Immunol       Date:  2016-03-28       Impact factor: 11.530

4.  Identification and editing of stem-like cells in methylcholanthrene-induced sarcomas.

Authors:  Emilie T E Gross; Carlos D Peinado; Yujin Jung; Semi Han; Beichen Liu; Endi K Santosa; Jack D Bui
Journal:  Oncoimmunology       Date:  2018-10-31       Impact factor: 8.110

Review 5.  The ancient cytokine IL-17D is regulated by Nrf2 and mediates tumor and virus surveillance.

Authors:  Ruth Seelige; Allen Washington; Jack D Bui
Journal:  Cytokine       Date:  2016-12-09       Impact factor: 3.861

6.  Nrf2 Induces IL-17D to Mediate Tumor and Virus Surveillance.

Authors:  Robert Saddawi-Konefka; Ruth Seelige; Emilie T E Gross; Eric Levy; Stephen C Searles; Allen Washington; Endi K Santosa; Beichen Liu; Timothy E O'Sullivan; Olivier Harismendy; Jack D Bui
Journal:  Cell Rep       Date:  2016-08-18       Impact factor: 9.423

7.  Involvement of nuclear factor erythroid 2‑related factor 2 in neonatal intestinal interleukin‑17D expression in hyperoxia.

Authors:  Xuying Liu; Dongyang Zhang; Qing Cai; Dongyan Liu; Siyu Sun
Journal:  Int J Mol Med       Date:  2020-08-07       Impact factor: 4.101

8.  Evaluation of IL-17D in Host Immunity to Group A Streptococcus Infection.

Authors:  Allen Washington; Nissi Varki; J Andrés Valderrama; Victor Nizet; Jack D Bui
Journal:  J Immunol       Date:  2020-10-19       Impact factor: 5.422

9.  Regulation of Murine Ovarian Epithelial Carcinoma by Vaccination against the Cytoplasmic Domain of Anti-Müllerian Hormone Receptor II.

Authors:  Cagri Sakalar; Suparna Mazumder; Justin M Johnson; Cengiz Z Altuntas; Ritika Jaini; Robert Aguilar; Sathyamangla V Naga Prasad; Denise C Connolly; Vincent K Tuohy
Journal:  J Immunol Res       Date:  2015-11-05       Impact factor: 4.818

Review 10.  Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression.

Authors:  Antonino Bruno; Lorenzo Mortara; Denisa Baci; Douglas M Noonan; Adriana Albini
Journal:  Front Immunol       Date:  2019-04-18       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.